^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Prostate Cancer

    Related cancers:
    18h
    Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Mayo Clinic | Trial completion date: May 2026 --> May 2027 | Trial primary completion date: May 2026 --> May 2027
    Trial completion date • Trial primary completion date
    20h
    Evaluation of a Prostate-Targeted PET Imaging System (P-PET) for Detecting Prostate Cancer (clinicaltrials.gov)
    P=N/A, N=25, Not yet recruiting, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
    New trial
    22h
    A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men (clinicaltrials.gov)
    P=N/A, N=200, Not yet recruiting, Mayo Clinic | Initiation date: Mar 2026 --> Mar 2027
    Trial initiation date
    1d
    HypProMet: Evaluation of Hypnosis in Virtual Reality on the Anxiety of Patients With Metastatic Prostate Cancer Over Chemotherapy (clinicaltrials.gov)
    P=N/A, N=53, Completed, Saint-Gregoire Private Hospital Center | Recruiting --> Completed | Trial completion date: Feb 2027 --> Feb 2026 | Trial primary completion date: Dec 2026 --> Dec 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    docetaxel
    1d
    Relationship between cathepsin K and extracellular matrix dynamics: a comprehensive review. (PubMed, Front Oncol)
    CTSK is a central hub integrating upstream signals to regulate systemic ECM homeostasis, making it a promising therapeutic target. Future therapeutic strategies should focus on developing highly selective inhibitors to achieve precise regulation and balance efficacy with safety.
    Review • Journal
    |
    CTSK (Cathepsin K)
    2d
    ASCERTAIN: A Study to Investigate the Biological Effects of Saruparib (AZD5305), Darolutamide, and in Combination in Men With Newly Diagnosed Prostate Cancer. (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Nubeqa (darolutamide) • saruparib (AZD5305)
    2d
    DUET study: DUET-study: A FEASIBILITY STUDY OF 177LU-PSMA RADIOLIGAND THERAPY ALTERNATED WITH RADIUM-223 IN PATIENTS WITH BONE-METASTATIC, OLIGO-METASTATIC HORMONE-SENSITIVE PROSTATE CANCER AFTER CURATIVE THERAPY. (2024-518985-29-02)
    P1/2, N=6, Completed, Amsterdam UMC Stichting | Active, not recruiting --> Completed
    Trial completion
    |
    FOLH1 expression
    |
    Xofigo (radium Ra-223 dichloride)
    2d
    2693-CL-2101: A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed by the Body in Men With Prostate Cancer (2024-520286-31-00)
    P1, N=56, Not yet recruiting, Astellas Pharma Global Development Inc.
    New P1 trial
    |
    Xtandi (enzalutamide) • bicalutamide • apalutamide
    3d
    FAERS based pharmacovigilance study and network pharmacology analysis of Lutathera and Pluvicto. (PubMed, Appl Radiat Isot)
    This FAERS analysis characterizes agent-specific safety profiles, informing pharmacovigilance strategies. Mechanistic profiling of adverse drug reactions optimizes evidence-based treatment, enhancing medication safety and refining benefit-risk profiles in clinical practice.
    Journal • Adverse events
    |
    ROR1 (Receptor Tyrosine Kinase Like Orphan Receptor 1) • SSTR (Somatostatin Receptor)
    |
    Pluvicto (lutetium Lu 177 vipivotide tetraxetan) • Lutathera (lutetium Lu 177 dotatate)
    3d
    Anticancer and Drug-Likeness Evaluation of Allylphenol-Based 15-LOX Inhibitors in Prostate Cancer: An In Vitro and Computational Study. (PubMed, Anticancer Agents Med Chem)
    These results highlight the anticancer properties of eugenol-derived allylphenol compounds. The compounds induce apoptosis by mechanisms independent of BAX/BCL-2 transcriptional modulation. Computational modeling suggests potential involvement of 15-LOX-1; nevertheless, direct mechanistic validation via caspase activity, ROS generation, or protein-level quantification of BAX/BCL-2 is necessary to verify the apoptotic pathway. The compounds suggest favorable pharmacokinetic profiles along with strong enzyme binding characteristics. Compound 38 exhibited the most balanced profile, characterized by high cytotoxicity, selectivity, and predicted ADME properties. Additional mechanistic investigations and in vivo validation are necessary to advance these candidates through preclinical development.
    Preclinical • Journal
    |
    BCL2 (B-cell CLL/lymphoma 2) • BAX (BCL2-associated X protein)
    4d
    Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection (clinicaltrials.gov)
    P=N/A, N=2000, Recruiting, Alliance for Clinical Trials in Oncology | Trial primary completion date: Jan 2026 --> Jan 2027
    Trial primary completion date
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    4d
    PROSINT: A Pilot Study of Ultra-High-Dose Hypofractionated or Single-Dose Radiotherapy for Intermediate Risk Prostate Cancer (clinicaltrials.gov)
    P1, N=31, Active, not recruiting, Albert Einstein College of Medicine | Phase classification: P2 --> P1
    Phase classification
    |
    dexamethasone